Cosmetic cross-reference

Berberine

CAS 2086-83-1

Berberine (CAS 2086-83-1) is a Phase 4 pharmaceutical compound with 10 bioactivity targets and 380 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

380

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Berberine

CAS Number

2086-83-1

UNII

0I8Y3P32UF

InChIKey

YBHILYKTIRIUTE-UHFFFAOYSA-N

ChEMBL ID

CHEMBL295124

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural productwithdrawn flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL295124 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 10 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	MIC	88.77784531914894 ug.mL-1	188	-
-	MIC	564885.4838709678 nM	62	-
-	IC50	20783.344727272728 nM	54	-
-	Potency	11357.220833333333 nM	22	-
-	EC50	2498 nM	15	-
-	Kd	4970 nM	10	-
-	Ki	5397.714285714285 nM	7	-
-	IC50	19.646 ug.mL-1	5	-
-	AC50	6704.336666666666 nM	3	-
-	Ki	1.095 10'-4/M	2	-

SOURCE IUPHAR/BPS 2 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
CYP1B1 CYP1B1	Inhibition	7.360000133514404 pKi	28458135
CYP2D6 CYP2D6	Inhibition	5.400000095367432 pIC50	32987920

SOURCE PharmGKB 1 phenotype row

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

CYP2D6 CYP2D6*1, CYP2D6*10

Evidence: 3; PMID 1

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Berberine used for in pharmaceutical contexts?

Berberine (CAS 2086-83-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Berberine?

Berberine has 380 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Atrial fibrillation, Bronchitis, Respiratory disorder, Abdominal discomfort, Abdominal distension. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Berberine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Berberine with EU status "permitted".

What clinical phase is Berberine in?

Berberine is rendered with ChEMBL max phase 4 (approved).